File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: A pilot study on tacrolimus treatment in membranous or quiescent lupus nephritis with proteinuria resistant to angiotensin inhibition or blockade

TitleA pilot study on tacrolimus treatment in membranous or quiescent lupus nephritis with proteinuria resistant to angiotensin inhibition or blockade
Authors
Issue Date2007
PublisherSage Publications Ltd. The Journal's web site is located at http://lup.sagepub.com
Citation
Lupus, 2007, v. 16 n. 1, p. 46-51 How to Cite?
AbstractPersistent proteinuria in patients with quiescent lupus can result from membranous lupus nephritis and/or glomerular scarring following previous flares. This pilot study examined the effects of tacrolimus over two years in six patients with membranous/inactive lupus nephritis and persistent proteinuria despite angiotensin inhibition/blockade. Tacrolimus treatment reduced proteinuria and increased serum albumin (time effect, P = 0.047 and 0.032 respectively). Compared with baseline levels, proteinuria improved by more than 50% in five patients (83.3%) and hypoalbuminaemia was corrected in four patients. The efficacy was most prominent in four patients with biopsy-proven membranous lupus nephritis, whose protienuria improved by over 80%. One patient developed biopsy-proven chronic nephrotoxicity after 10 months of tacrolimus treatment, despite non-excessive blood levels. These data suggest that tacrolimus is an effective treatment for proteinuria due to membranous lupus nephritis, but should probably be reserved for patients who are refractory to other non-nephrotoxic treatments, in view of the potential risk of subclinical nephrotoxicity. © 2007 SAGE Publications.
Persistent Identifierhttp://hdl.handle.net/10722/163058
ISSN
2015 Impact Factor: 2.118
2015 SCImago Journal Rankings: 0.878
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorTse, KCen_US
dc.contributor.authorLam, MFen_US
dc.contributor.authorTang, SCWen_US
dc.contributor.authorTang, CSOen_US
dc.contributor.authorChan, TMen_US
dc.date.accessioned2012-09-05T05:27:04Z-
dc.date.available2012-09-05T05:27:04Z-
dc.date.issued2007en_US
dc.identifier.citationLupus, 2007, v. 16 n. 1, p. 46-51en_US
dc.identifier.issn0961-2033en_US
dc.identifier.urihttp://hdl.handle.net/10722/163058-
dc.description.abstractPersistent proteinuria in patients with quiescent lupus can result from membranous lupus nephritis and/or glomerular scarring following previous flares. This pilot study examined the effects of tacrolimus over two years in six patients with membranous/inactive lupus nephritis and persistent proteinuria despite angiotensin inhibition/blockade. Tacrolimus treatment reduced proteinuria and increased serum albumin (time effect, P = 0.047 and 0.032 respectively). Compared with baseline levels, proteinuria improved by more than 50% in five patients (83.3%) and hypoalbuminaemia was corrected in four patients. The efficacy was most prominent in four patients with biopsy-proven membranous lupus nephritis, whose protienuria improved by over 80%. One patient developed biopsy-proven chronic nephrotoxicity after 10 months of tacrolimus treatment, despite non-excessive blood levels. These data suggest that tacrolimus is an effective treatment for proteinuria due to membranous lupus nephritis, but should probably be reserved for patients who are refractory to other non-nephrotoxic treatments, in view of the potential risk of subclinical nephrotoxicity. © 2007 SAGE Publications.en_US
dc.languageengen_US
dc.publisherSage Publications Ltd. The Journal's web site is located at http://lup.sagepub.comen_US
dc.relation.ispartofLupusen_US
dc.rightsLupus. Copyright © Sage Publications Ltd.-
dc.subject.meshAdulten_US
dc.subject.meshAngiotensin-Converting Enzyme Inhibitors - Therapeutic Useen_US
dc.subject.meshAntibodies, Antinuclear - Blooden_US
dc.subject.meshAutoantigens - Immunologyen_US
dc.subject.meshBlood Glucose - Analysisen_US
dc.subject.meshBlood Pressure - Drug Effectsen_US
dc.subject.meshComplement C3 - Analysisen_US
dc.subject.meshCreatinine - Blooden_US
dc.subject.meshDna - Immunologyen_US
dc.subject.meshDrug Evaluationen_US
dc.subject.meshDrug Resistanceen_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshHypoalbuminemia - Drug Therapy - Etiologyen_US
dc.subject.meshImmunosuppressive Agents - Adverse Effects - Therapeutic Useen_US
dc.subject.meshKidney Diseases - Chemically Induceden_US
dc.subject.meshLipids - Blooden_US
dc.subject.meshLupus Nephritis - Blood - Classification - Complications - Drug Therapy - Pathologyen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshMycophenolic Acid - Analogs & Derivatives - Therapeutic Useen_US
dc.subject.meshPilot Projectsen_US
dc.subject.meshPrednisolone - Therapeutic Useen_US
dc.subject.meshProteinuria - Drug Therapy - Etiologyen_US
dc.subject.meshRetrospective Studiesen_US
dc.subject.meshSerum Albumin - Analysisen_US
dc.subject.meshTacrolimus - Adverse Effects - Therapeutic Useen_US
dc.subject.meshTreatment Outcomeen_US
dc.titleA pilot study on tacrolimus treatment in membranous or quiescent lupus nephritis with proteinuria resistant to angiotensin inhibition or blockadeen_US
dc.typeArticleen_US
dc.identifier.emailTang, SCW:scwtang@hku.hken_US
dc.identifier.emailChan, TM:dtmchan@hku.hken_US
dc.identifier.authorityTang, SCW=rp00480en_US
dc.identifier.authorityChan, TM=rp00394en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1177/0961203306073167en_US
dc.identifier.pmid17283585en_US
dc.identifier.scopuseid_2-s2.0-33846613753en_US
dc.identifier.hkuros132108-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-33846613753&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume16en_US
dc.identifier.issue1en_US
dc.identifier.spage46en_US
dc.identifier.epage51en_US
dc.identifier.isiWOS:000243773100008-
dc.publisher.placeUnited Kingdomen_US
dc.identifier.scopusauthoridTse, KC=7102609864en_US
dc.identifier.scopusauthoridLam, MF=35300050600en_US
dc.identifier.scopusauthoridTang, SCW=7403437082en_US
dc.identifier.scopusauthoridTang, CSO=8681865300en_US
dc.identifier.scopusauthoridChan, TM=7402687700en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats